ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 0278 • ACR Convergence 2024

    Efficacy and Safety of Genakumab versus Compound Betamethasone in Gout: The GUARD-1 Study

    Yu Xue1, Tianshu Chu2, Jiankang Hu3, Wei Gou4, Ning Zhang5, Juan Li6, Jing Yu7, Songping Li8, Songbin Li9, Long Qian10, Xinwang Duan11, Lihua Duan12 and Hejian Zou1, 1Department of Rheumatology, Huashan Hospital, Fudan University, Shanghai, China, Shanghai, China (People's Republic), 2Department of Rheumatology, Henan Provincial People's Hospital, Zhengzhou, China, Zhengzhou, China (People's Republic), 3Department of Rheumatology, Pingxiang People's Hospital, Pingxiang, China, Pingxiang, China (People's Republic), 4Department of Rheumatology, Hebei Petro China Central Hospital, Langfang, China, Langfang, China (People's Republic), 5Department of Rheumatology, Shengjing Hospital of China Medical University, Shenyang, China, Shenyang, China (People's Republic), 6Department of Rheumatology, The First Affiliated Hospital of Hainan Medical University, Haikou, China, Haikou, China (People's Republic), 7Department of Rheumatology, The First Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, Shenyang, China, Shenyang, China (People's Republic), 8Department of Rheumatology, The First Affiliated Hospital of Ganna Medical University, Ganzhou, China, Ganzhou, China (People's Republic), 9Department of Rheumatology, The First Hospital of Qiqihar, Qiqihar, China, Qiqihar, China (People's Republic), 10Department of Rheumatology, The Second Hopital of Anhui Medical University, Hefei, China, Hefei, China (People's Republic), 11Department of Rheumatology, The Second Affiliated Hospital of Nanchang University, Nanchang, China, Nanchang, China (People's Republic), 12Department of Rheumatology, Jiangxi Provincial People's Hospital, Nanchang, China, Nanchang, China (People's Republic)

    Background/Purpose: The GUARD (Genakumab in high Uric Acid-induced Arthritis/goutfor Resolution and Delay study) program was designed to investigate the efficacy and safety of Genakumab, a…
  • Abstract Number: 0290 • ACR Convergence 2024

    Deucravacitinib Long-term Efficacy Through 4 Years in Week 16 Placebo Crossover Patients in the Phase 3 POETYK PSO-1, PSO-2, and LTE Program

    Mark Lebwohl1, Richard Warren2, Shinichi Imafuku3, Jerry Bagel4, April W. Armstrong5, Thierry Passeron6, Subhashis Banerjee7, Renata M. Kisa8, Matthew J. Colombo7, Thomas Scharnitz8, Kim Hoyt8, Diamant Thaçi9 and Andrew Blauvelt10, 1Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, 2Dermatology Centre, Northern Care Alliance NHS Foundation Trust and NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, 3Fukuoka University Hospital Faculty of Medicine, Fukuoka, Japan, 4Psoriasis Treatment Center of New Jersey, East Windsor, 5University of California Los Angeles, Los Angeles, 6Université Côte d’Azur, University Hospital of Nice, Nice, France, 7Bristol Myers Squibb, Princeton, NJ, 8Bristol Myers Squibb, Princeton, 9Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Schleswig-Holstein, Germany, 10Oregon Medical Research Center, Portland, OR

    Background/Purpose: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, is approved in the US, EU, and other countries for treatment of adults with moderate…
  • Abstract Number: 0295 • ACR Convergence 2024

    Mycophenolate Mofetil in the Treatment of Patients with Isolated Cardiac Sarcoidosis

    Namitha Nair1, Leen Al Saleh2, Haya Haddad3, Maria Jaimes Reyes4, Vishakha Chetram5, Farooq Sheikh6, FLORINA CONSTANTINESCU7 and Anjani Pillarisetty8, 1University of Pittsburgh Medical Center, Pittsburgh, PA, 2Watson Clinic, Lakeland, FL, 3Medstar Washington Hospital Center, Silver Spring, MD, 4Medstar Washington Hospital Center/Georgetown University, Washington, DC, 5Inova Schar Heart and Vascular, Falls Chirch, VA, 6MedStar Heart and Vascular Institute, Georgetown University School of Medicine, Washington, DC, 7MedStar Washington Hospital Center, Washington, DC, 8Carson Tahoe Medical Group, Reno, NV

    Background/Purpose: Cardiac involvement is seen in approximately a fourth of patients with sarcoidosis, a non-necrotizing granulomatous systemic disease. Among these patients, 25% may have isolated cardiac…
  • Abstract Number: 0335 • ACR Convergence 2024

    Analysis of the Prevalence of Diabetes Mellitus in Patients with Adult-onset Dermatomyositis

    Komal Ejaz1, Chao Zhang2 and Soumya Chatterjee3, 1Cleveland Clinic, Cleveland, OH, 2Cleveland Clinic, Cleveland Heights, OH, 3Cleveland Clinic, Richmond Heights, OH

    Background/Purpose: Dermatomyositis is an idiopathic inflammatory myopathy with proximal muscle weakness and skin manifestations. Myositis patients have poor overall health partially due to co-morbidities. Data…
  • Abstract Number: 0339 • ACR Convergence 2024

    Clinical Characteristics Associated with Inpatient Mortality in Dermatomyositis Patients: A Single Center Retrospective Cohort Study

    Anjana Srikumar, Keon Niknejad, Maria Kaltchenko and Jun Kang, Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose: Dermatomyositis (DM) is a rare autoimmune disease associated with higher rates of hospitalization, longer lengths of stay, higher mean hospitalization costs, and increased inpatient…
  • Abstract Number: 0243 • ACR Convergence 2024

    Humoral Response to SARS-CoV-2 Vaccination and Breakthrough COVID-19 Disease in Patients with Immune-mediated Inflammatory Diseases Receiving Biological Treatment

    Eve-Kai Raussi, Maigi Eisen, Küllike Palk and Marge Kütt, North Estonia Medical Centre Foundation, Tallinn, Estonia

    Background/Purpose: Immune response in patients with immune-mediated inflammatory diseases (IMID) is compromised. As SARS-CoV-2 vaccine trials excluded patients on immunosuppressive therapy, data about vaccination efficacy…
  • Abstract Number: 0337 • ACR Convergence 2024

    Characterization of Statin Induced Myopathy in the Hospital Setting

    Olivia Yang1, KUMAR VENKAT2, Jeffery Durbin3 and Scott Kubomoto1, 1Riverside Community Hospital, Riverside, CA, 2Voluntary Clinical Associate Professor of Medicine -UCRSOM, Riverside, California, IRVINE, CA, 3HCA Healthcare Physicians Services Group, Brentwood, TN

    Background/Purpose: Adverse effects of statin use involve the muscle and related rhabdomyolysis. Known risk factors for rhabdomyolysis include female sex, older age, Asian race, hypothyroidism,…
  • Abstract Number: 0297 • ACR Convergence 2024

    Characteristics of Adult-Onset Still’s Disease Skin Eruption in Individuals of Sub-Saharan Ancestry

    Benoit Suzon1, Eleonore de Fritsch1, Arthur Felix1, Fabienne Louis-sidney2, Emmanuelle Amazan1, Florence Moinet3, Aurore Abel1, Illitch Coco-Viloin1, Moustapha Dramé1, Christophe Deligny4 and Pernelle Thomas1, 1University Hospital of Martinique, Fort-de-France, Martinique, 2University Hospital Martinique, Fort De France, Martinique, 3University Hospital of Martinique, Fort de France, France, 4University Hospital of Martinique - National reference center for autoimmune disease, Internal Medicine, Fort-de-France, Martinique

    Background/Purpose: There is no data about adult-onset Still's disease (AOSD) skin eruption in individuals of sub-Saharan ancestry, from basic description to potential clinical implications.Methods: We conducted…
  • Abstract Number: 0375 • ACR Convergence 2024

    Patient Outcomes During the Implementation of a Patient Decision-Aid for a Diverse Population of Systemic Lupus Erythematosus: A Study in 15 U.S. Rheumatology Clinics

    Jasvinder Singh1, Larry Hearld2, Walter Chatham3, Sonali Narain4, Narender Annapureddy5, Diane Kamen6, Kimberly Trotter7, vikas Majithia8, Zineb Aouhab9, Swamy Venuturupalli10, Daniel Wallace11, rosalind Ramsey-Goldman12, Alfred Kim13, Maureen McMahon14, S. Sam Lim15, Kalpana Bhairavarasu16, Alexa Meara17, Kenneth Kalunian18 and Cathy Lee Ching19, 1Baylor College of Medicine, Birmingham, AL, 2University of Alabama at Birmingham (UAB), Birmingham, AL, 3University of Nevada, Las Vegas, Las Vegas, NV, 4Northwell Health, Great Neck, NY, 5Vanderbilt University Medical Center, Nashville, TN, 6Medical University of South Carolina, Charleston, SC, 7University of Chicago, Chicago, IL, 8University of Missisippi Medical Center (UMC), Jackson, MS, 9Loyola University Medical Center, Oak Brook, IL, 10Attune Health, Beverly Hills, CA, 11Cedars Sinai Medical Center, Studio City, CA, 12Northwestern University, Chicago, IL, 13Washington University School of Medicine, Division of Rheumatology, Department of Medicine, St Louis, MO, 14UCLA David Geffen School of Medicine, Los Angeles, CA, 15Emory University, Atlanta, GA, 16Baylor College of Medicine, Sugar Land, TX, 17The Ohio State University Wexner Medical Center, COLUMBUS, OH, 18University of California San Diego, La Jolla, CA, 19UMMC, Jackson, MS

    Background/Purpose: To implement a self-administered patient decision-aid (PtDA) for lupus in outpatient clinics, assess its reach/penetration within each clinic, and examine patient outcomesMethods: An effective…
  • Abstract Number: 0393 • ACR Convergence 2024

    Effectiveness of Secukinumab in TMJ Symptoms in Children with JPsA and ERA: A Secondary Data Analysis of JUNIPERA

    Marianne Kerski1, Smriti Mohan1, Cynthia Vizcaya2, Reema Sutariya3, Weibin Bao3 and Matthew Stoll4, 1University of Michigan, Ann Arbor, MI, 2Novartis Pharmaceutical Corporation, East Hanover, NJ, 3Novartis Pharmaceuticals Corporation, East Hanover, NJ, 4University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Early recognition and treatment of temporomandibular joint (TMJ) arthritis in children with juvenile idiopathic arthritis (JIA) is of high importance given its impact on…
  • Abstract Number: 0354 • ACR Convergence 2024

    Factors Associated with Health Information Technology Use Among United States Adults with Arthritis from 2012-2017: Analysis of the National Health Interview Survey

    Sarah Lieber1, Jerad Moxley2, M. Carrington Reid2 and Sara Czaja2, 1Hospital for Special Surgery, New York, NY, 2Weill Cornell Medicine, New York, NY

    Background/Purpose: Health information technology (HIT) use has been associated with numerous benefits including improvements in quality of care and patient safety. Factors associated with HIT…
  • Abstract Number: 0253 • ACR Convergence 2024

    Outcomes of Respiratory Syncytial Virus Infection in Patients with Systemic Autoimmune Rheumatic Diseases

    Justine Enns1, Shruthi Srivatsan1, Bohang Jiang1, Miao Lin1, Emily Kowalski2, Naomi Patel1, Xiaosong Wang3, Zachary Williams1, Grace Qian3, Jennifer Hanberg1, Colebrook Johnson1, Madison Negron1, Katarina Bade2, Alene Saavedra2, Kevin Mueller2, Kathleen Vanni3, Jeffrey Sparks4 and Zachary Wallace5, 1Massachusetts General Hospital, Boston, MA, 2Brigham and Women's Hospital, Boston, MA, 3Brigham and Women’s Hospital, Boston, MA, 4Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA, 5Massachusetts General Hospital, Newton, MA

    Background/Purpose: Respiratory Syncytial Virus (RSV) can cause a severe respiratory illness, especially in older adults and those with significant comorbidities. In June 2023 the US…
  • Abstract Number: 0346 • ACR Convergence 2024

    Clonally Expanded and Total B Cells in Patients with Idiopathic Inflammatory Myopathies Show Skewed B Cell Subset Distribution and Reduced Somatic Hypermutation Relative to Healthy Controls

    Amelia Sawyers1, Leslie Crofford2, Erin Wilfong3 and Rachel Bonami3, 1Vanderbilt University School of Medicine, Nashville, TN, 2Vanderbilt University Medical Center, Melbourne, AR, 3Vanderbilt University Medical Center, Nashville, TN

    Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a collection of rare, systemic rheumatic diseases. A role for B cells in IIM is indicated by the success…
  • Abstract Number: 0394 • ACR Convergence 2024

    Unveiling Major Challenges and Unmet Needs in the Therapeutic Approach to Systemic Juvenile Idiopathic Arthritis: The Patient Perspective

    Francesco Baldo1, Luciana Peixoto2, Remco Erkens3, Greta Rogani3, Claudia Bracaglia4, Dirk Foell5, Marco Gattorno6, Marija Jelusic7, Sebastiaan Vastert3, Rashmi Sinha2 and Francesca Minoia8, and on behalf of the PReS MAS/sJIA Working Party and the Systemic JIA Foundation, 1Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, 2Systemic JIA Foundation, Cincinnati, OH, 3University Medical Center Utrecht, Utrecht, Netherlands, 4IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, 5University Hospital Muenster, Muenster, Germany, 6IRCCS Giannina Gaslini, Genoa, Italy, 7University of Zagreb School of Medicine, University Hospital Centre Zagreb, Zagreb, Zagreb, Croatia, 8Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Milan, Italy

    Background/Purpose: Despite continuous improvements in the therapeutic options for children with systemic juvenile idiopathic arthritis (sJIA), access to medications significantly differs among centres and countries.…
  • Abstract Number: 0360 • ACR Convergence 2024

    What Happens in Rheumatoid Arthritis Treatment Adherence, Two Years After the Introduction of Targeted Therapy? Results from the STRATEGE2 Study

    Cécile Gaujoux-Viala1, Emmanuelle Dernis2, Eric Senbel3 and René-Marc Flipo4, 1CHU Nîmes, Nïmes, Languedoc-Roussillon, France, 2CH LE MANS, LE MANS, Pays de la Loire, France, 3Cabinet de Rhumatologie, Marseille, France, 4Hôpital Roger Salengro, France, Lille, France

    Background/Purpose: Treatment adherence is a major challenge in chronic inflammatory rheumatic diseases, particularly rheumatoid arthritis (RA), with adherence rates ranging from 30 to 80%. Given…
  • « Previous Page
  • 1
  • …
  • 77
  • 78
  • 79
  • 80
  • 81
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology